Status:
TERMINATED
A Study on the Angioarchitecture of Hepatocellular Carcinoma
Lead Sponsor:
Chinese University of Hong Kong
Conditions:
Carcinoma, Hepatocellular
Eligibility:
All Genders
19+ years
Phase:
NA
Brief Summary
Hepatocellular carcinoma (HCC) is one of the commonest solid malignancies in Hong Kong as well as globally. Transarterial therapy has been playing an important role in the treatment algorithm for pati...
Detailed Description
Embolization is performed within 2 weeks before the scheduled date of partial hepatectomy. The purpose of the timing is two folded, it allows observation of the embolization effect to be differentiate...
Eligibility Criteria
Inclusion
- Age above 18 years
- HCC suitable for partial hepatectomy
- Child-Pugh A or B cirrhosis
- Eastern Cooperative Oncology Group performance score 0 or 1
- Barcelona clinic liver cancer (BCLC) staging A or B
- HCC diagnosed by typical enhancement patterns on cross sectional imaging or histology
- Massive expansive tumor morphology with measurable lesion on CT (characterized by well-defined spherical or globular configuration, with or without tumor capsule or satellite lesions)
Exclusion
- Previous treatment with liver resection, ablation, chemotherapy, radiotherapy or transarterial embolization (with or without chemotherapy),
- Evidence of tumor invasion of portal vein or hepatic vein
- History of acute tumor rupture presenting with hemo-peritoneum
- Infiltrative tumor morphology (characterized by ill- defined tumor margin and amorphous configuration) or diffuse tumor morphology (characterized by large number of small nodules)
- Serum creatinine level \> 150umol/L
Key Trial Info
Start Date :
August 13 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 17 2023
Estimated Enrollment :
32 Patients enrolled
Trial Details
Trial ID
NCT03808766
Start Date
August 13 2018
End Date
April 17 2023
Last Update
May 3 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Imaging and Interventional Radiology, Prince of Wales Hospital, The Chinese University of Hong Kong
Hong Kong, Hong Kong